CRBP
Corbus Pharmaceuticals Holdings Inc.
$11.50
-$0.12(-1.03%)
46
Overall
--
Value
58
Tech
34
Quality
Market Cap
$125.86M
Volume
283.54K
52W Range
$4.64 - $23.33
Target Price
$40.67
Order:
Income Statement
| Metric | Trend | Chart | 2015 Dec | 2016 Dec | 2017 Dec | 2018 Dec | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||||||
| Total Revenue | $648.4K | $1.9M | $2.4M | $4.8M | $36.1M | $3.9M | $881.7K | -- | -- | -- | ||
| Total Revenue | $648.4K | $1.9M | $2.4M | $4.8M | $36.1M | $3.9M | $881.7K | -- | -- | -- | ||
| GROSS PROFIT | ||||||||||||
| Gross Profit | $648.4K | $1.9M | $2.4M | $4.8M | $36.1M | $3.9M | $881.7K | -- | -- | -- | ||
| OPERATING EXPENSES | ||||||||||||
| Operating Expenses | $-9.5M | $-21.9M | $-35.0M | $-61.6M | $113.2M | $126.7M | $56.9M | $34.8M | $45.1M | $48.7M | ||
| Research & Development | $5.9M | $15.4M | $26.0M | $48.6M | $89.6M | $98.3M | $36.4M | $16.1M | $31.2M | $32.2M | ||
| Research Expense | $5.9M | $15.4M | $26.0M | $48.6M | $89.6M | $98.3M | $36.4M | $16.1M | $31.2M | $32.2M | ||
| Selling, General & Administrative | $3.6M | $6.5M | $9.0M | $13.0M | $23.6M | $28.5M | $20.4M | $18.7M | $13.9M | $16.5M | ||
| General & Administrative Expenses | $3.6M | $6.5M | $9.0M | $13.0M | $23.6M | $28.5M | $20.4M | $18.7M | $13.9M | $16.5M | ||
| Salaries & Wages | $-1.2M | $-3.2M | $-5.7M | $-7.6M | $-12.0M | $12.5M | $9.5M | $5.7M | $3.5M | $6.1M | ||
| Depreciation & Amortization | $-44.0K | $-87.7K | $-255.7K | $-493.9K | $-739.4K | $1.1M | $1.0M | $763.0K | $600.0K | $600.0K | ||
| Depreciation & Amortization | $-44.0K | $-87.7K | $-255.7K | $-493.9K | $-739.4K | $1.1M | $1.0M | $763.0K | $600.0K | $600.0K | ||
| Other Operating Expenses | -- | $-21.9M | $-35.0M | -- | $-1.0M | $1.2M | $1.2M | $39.8M | $45.1M | $48.7M | ||
| OPERATING INCOME | ||||||||||||
| Operating income | $-8.9M | $-20.0M | $-32.6M | $-56.7M | $-77.1M | $-122.8M | $-56.0M | $-39.8M | $-45.1M | $-48.7M | ||
| EBITDA | $-8.8M | $-19.9M | $-32.2M | $-55.2M | $-71.5M | $-121.1M | $-54.3M | $-34.1M | $-39.3M | $-37.4M | ||
| NON-OPERATING ITEMS | ||||||||||||
| Interest Expense (Non-Operating) | $-2.4K | $-3.1K | $-3.6K | -- | $-1.2M | $1.0M | $1.8M | $2.1M | $3.8M | $1.8M | ||
| Intinc | $977 | $477 | $183.1K | $982.8K | $4.6M | -- | -- | -- | -- | -- | ||
| Net Non-Operating Interest Income/Expense | $977 | $477 | $183.1K | $982.8K | $5.8M | $-1.0M | $-1.8M | $-2.1M | $-3.8M | $-1.8M | ||
| Gain on Sale of Securities | -- | -- | -- | -- | -- | $-251.0K | $663.3K | $96.8K | $1.6M | $6.3M | ||
| Other Income/Expense | -- | -- | -- | $-6.2M | $-4.6M | $-13.0M | $-12.5M | $-5.4M | $-4.5M | $-10.4M | ||
| Other Special Charges | -- | -- | -- | $6.2M | $4.6M | $13.3M | $11.9M | $-48.8K | $2.7M | $4.1M | ||
| SPECIAL ITEMS | ||||||||||||
| Special Income Charges | -- | -- | -- | -- | -- | -- | -- | $-5.0M | -- | -- | ||
| PRE-TAX INCOME | ||||||||||||
| EBIT | $-8.9M | $-20.0M | $-32.4M | $-55.7M | $-72.7M | $-122.8M | $-56.0M | $-34.8M | $-40.8M | $-38.4M | ||
| Pre-Tax Income | $-8.9M | $-20.0M | $-32.4M | $-55.7M | $-71.5M | $-111.3M | $-45.7M | $-42.3M | $-40.6M | $-40.2M | ||
| NET INCOME | ||||||||||||
| Net Income | $-8.9M | $-20.0M | $-32.4M | $-55.7M | $-71.5M | $-111.3M | $-45.6M | $-42.3M | $-44.6M | $-40.2M | ||
| Net Income (Continuing Operations) | $-8.9M | $-20.0M | $-32.4M | $-55.7M | $-71.5M | $-111.3M | $-45.6M | $-42.3M | $-44.6M | $-40.2M | ||
| Net Income (Discontinued Operations) | $-8.9M | $-20.0M | $-32.4M | $-55.7M | $-71.5M | $-111.3M | $-45.6M | $-42.3M | $-44.6M | $-40.2M | ||
| Net Income (Common Stockholders) | $-8.9M | $-20.0M | $-32.4M | $-55.7M | $-71.5M | $-111.3M | $-45.6M | $-42.3M | $-44.6M | $-40.2M | ||
| Normalized Income | -- | -- | -- | -- | -- | -- | $-36.1M | -- | -- | $-37.9M | ||
| TOTALS | ||||||||||||
| Total Expenses | $-9.5M | $-21.9M | $-35.0M | $-61.6M | $113.2M | $126.7M | $56.9M | $34.8M | $45.1M | $48.7M | ||
| SHARE & EPS DATA | ||||||||||||
| Average Shares Outstanding | $1.0M | $1.4M | $1.7M | $1.9M | $2.1M | $2.6M | $4.1M | $4.2M | $4.3M | $10.9M | ||
| Average Shares Outstanding (Diluted) | $1.1M | $1.4M | $1.7M | $1.9M | $2.1M | $2.6M | $4.1M | $4.2M | $4.3M | $10.9M | ||
| Shares Outstanding | $1.3M | $1.6M | $1.9M | $2.1M | $2.4M | $4.2M | $4.2M | $4.2M | $10.5M | $12.3M | ||
| Basic EPS | -- | -- | -- | -- | -- | $-42.6 | $-11.1 | $-10.15 | $-10.31 | $-3.68 | ||
| Basic EPS (Continuing Operations) | -- | -- | -- | -- | -- | $-42.6 | $-11.1 | $-10.15 | $-10.31 | $-3.68 | ||
| Diluted EPS | $-8.4 | $-14.7 | $-19.5 | $-29.4 | $-33.6 | $-42.6 | $-11.1 | $-10.15 | $-10.31 | $-3.68 | ||
| Diluted EPS (Continuing Operations) | -- | -- | -- | -- | $-33.6 | -- | -- | $-10.15 | $-10.31 | $-3.68 | ||
| OTHER METRICS | ||||||||||||
| Net Income Discontinuous Operations | -- | $34.5K | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Non Recurring Operation Expense | -- | -- | -- | -- | -- | -- | -- | $5.0M | -- | -- | ||
| Other Gand A | $3.6M | $6.5M | $9.0M | $13.0M | $23.6M | $28.5M | $20.4M | $18.7M | $13.9M | $16.5M | ||
| Provision For Gain Loss On Disposal | -- | $34.5K | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Rent And Landing Fees | $3.6M | $6.5M | $9.0M | $13.0M | $-1.1M | -- | -- | -- | $-1.7M | $-1.7M | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | CRBP | $11.50 | -1.0% | 283.54K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Corbus Pharmaceuticals Holdings Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW